WO 2004/024213 PCT/US2003/028889

WHAT IS CLAIMED IS:

1 1. A system comprising capreomycin and a device for introducing said 2 capreomycin into gases for inhalation by a person in need thereof.

- 2. A system of claim 1, wherein said capreomycin is introduced into said gases as a solution, a suspension, a powder, or a spray.
- 1 3. A system of claim 1, wherein said device is a nebulizer, a metered dose inhaler, or a dry powder inhaler.
- 4. A system of claim 3, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi nebulizer, and a refillable nebulizer.
- 5. A system of claim 1, wherein said capreomycin is introduced into said gases in an average particle size of between 1 and 10 microns.
- 1 6. A system of claim 5, wherein said capreomycin has an average particle 2 size of between 2 and 6 microns.
- 7. A system of claim 5, wherein said capreomycin has an average particle size of about 3 to about 5 microns.
- 8. A system of claim 1, wherein said capreomycin is provided as a powder.
- 9. A system of claim 8, wherein said capreomycin is introduced into said gases in an average particle size of between 1 and 10 microns.
- 1 10. A system of claim 9, wherein said capreomycin has an average particle 2 size of about 3 to about 5 microns.
- 1 11. A formulation of capreomycin suitable for aerosol administration.
- 1 12. A formulation of capreomycin of claim 11, wherein said capreomycin 2 has an average particle size between 1 and 10 microns.

WO 2004/024213 PCT/US2003/028889

A formulation of capreomycin of claim 12, wherein said capreomycin 1 13. 2 is complexed or associated with a polysaccharide.

- 14. A method of inhibiting the growth of Mycobacterium tuberculosis 1 ("MTB"), said method comprising introducing capreomycin into gases to be inhaled by a 2 3 patient in need thereof.
- 1 15. A method of claim 14, wherein said capreomycin is introduced into 2 said gases as a solution, a suspension, a powder, or a spray.
- 1 16. A method of claim 14, wherein said capreomycin introduced into said 2 gases in an average particle size of between 1 and 10 microns.
- 1 17. A method of claim 14, wherein said capreomycin is complexed or 2 associated with a polysaccharide.
- A method of claim 14, wherein said capreomycin is introduced into 1 . 18. said gases by a nebulizer, a metered dose inhaler, or a dry powder inhaler. 2
- 19. A method of claim 18, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi 3 nebulizer, and a refillable nebulizer.

1

2

- 20. A method of inhibiting the growth of Mycobacterium tuberculosis 1 2 ("MTB") in a patient, said method comprising administering to a lung of said patient 3 aerosolized capreomycin, wherein said capreomycin inhibits the growth of MTB in said 4 patient.
- 1 21. A method of claim 20, wherein said capreomycin is administered to 2 said lung as a solution, a suspension, a powder, or a spray.
- A method of claim 20, wherein said capreomycin is administered to 22. 1 said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler. 2
- 1 23. A method of claim 22, wherein said nebulizer is selected from the group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi 2 nebulizer, and a refillable nebulizer. 3

WO 2004/024213 PCT/US2003/028889

1	24. A m	nethod of reducing infectivity of a person infected with
2	Mycobacterium tuberculosis ("MTB"), said method comprising administering to the lung of	
3	said person aerosolized capreomycin, wherein said capreomycin reduces the infectivity of	
4	said person.	·
1	25. A m	nethod of claim 24, wherein said capreomycin is administered to
2	said lung as a solution, a suspension, a powder, or a spray.	
1	26. A m	nethod of claim 24, wherein said capreomycin is administered to
2	said lung by a nebulizer, a metered dose inhaler, or a dry powder inhaler.	
1	27. A m	nethod of claim 26, wherein said nebulizer is selected from the
2	group consisting of a heated nebulizer, an ultrasonic nebulizer, a gas nebulizer, a venturi	
3	nebulizer, and a refillable nebulizer.	
1	28. A u	se of capreomycin for manufacture of a medicament for aerosolized
2	administration to a lung as a solution, a suspension, a powder, or a spray.	
1	29. A u	se of claim 28, wherein said medicament is suitable for delivery to
2	said lung by a nebulizer, a	metered dose inhaler, or a dry powder inhaler.
1	30. A fo	ormulation of lyophilized capreomycin having an average particle
2	size of from about 1 to about 10 microns.	